Blood Tests Instead of Bone Marrow Biopsy for Blood Disorders
Part of Blood & lymphatic clinical trials.
This study tests whether doctors can diagnose myeloproliferative neoplasms (slow-growing blood cancers like polycythemia vera, essential thrombocythemia, or myelofibrosis) using a simple blood test instead of a painful bone marrow biopsy. If successful, patients could get diagnosed faster and more comfortably.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been newly diagnosed with or are suspected to have one of three blood disorders: polycythemia vera, essential thrombocythemia, or primary myelofibrosis
- You have not yet started any treatment for your blood disorder
- You have not had a bone marrow transplant in the past
- Your doctor has referred you for a bone marrow biopsy to confirm your diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
This study looks at how 'epigenetic age' (a measure of certain changes in your DNA) relates to the way blood cancers called myeloproliferative neoplasms (MPNs) develop and progress. It may help doctors better understand and predict the course of these diseases.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.